Ablynx NV (XBRU:ABLXS) EBIT per Share : €-2.35 (TTM As of Dec. 2017)

View and export this data going back to . Start your Free Trial

What is Ablynx NV EBIT per Share?

Ablynx NV's EBIT per Share for the six months ended in Dec. 2017 was €-1.84. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2017 was €-2.35.

During the past 3 years, the average EBIT per Share Growth Rate was -44.10% per year. During the past 5 years, the average EBIT per Share Growth Rate was -7.70% per year. During the past 10 years, the average EBIT per Share Growth Rate was 3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Ablynx NV's EBIT per Share or its related term are showing as below:

XBRU:ABLXS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -44.1 Med: -0.8 Max: 34.6
Current: -44.1

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Ablynx NV was 34.60% per year. The lowest was -44.10% per year. And the median was -0.80% per year.

XBRU:ABLXS's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.4 vs XBRU:ABLXS: -44.10

Ablynx NV's EBIT for the six months ended in Dec. 2017 was €-79.47 Mil.

Ablynx NV EBIT per Share Historical Data

The historical data trend for Ablynx NV's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV EBIT per Share Chart

Ablynx NV Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

EBIT per Share

Get a 7-Day Free Trial

-0.45

-0.29

-1.16

0.14

-2.31

Ablynx NV Semi-Annual Data
	Dec07	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17
EBIT per Share	Get a 7-Day Free Trial															-1.02	0.61	-0.47	-0.50	-1.84

Ablynx NV EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Ablynx NV's EBIT per Share for the fiscal year that ended in Dec. 2017 is calculated as

	EBIT per Share		(A: Dec. 2017 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-101.105	/	43.708
=	-2.31

Ablynx NV's EBIT per Share for the quarter that ended in Dec. 2017 is calculated as

	EBIT per Share		(Q: Dec. 2017 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-79.472	/	43.120
=	-1.84

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2017 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.35

Ablynx NV (XBRU:ABLXS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Ablynx NV EBIT per Share Related Terms

Thank you for viewing the detailed overview of Ablynx NV's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Ablynx NV (XBRU:ABLXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ablynx.com

Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV (XBRU:ABLXS) Headlines

No Headlines